Post-hoc analyses of Spiolto Respimat (olodaterol + tiotropium) show improvements in COPD- Boehringer Ingelheim

Boehringer Ingelheim announced the presentation of several new post-hoc analyses from the TONADO 1 & TONADO 2 and OTEMTO 1 & OTEMTO 2 studies of Spiolto Respimat (olodaterol + tiotropium) in COPD. One analysis showed significant lung function improvement, as measured by FEV1 AUC0–3, with once daily Spiolto Respimat in COPD patients requiring maintenance treatment across a range of age groups, including those over 65 years of age.

In addition, a second analysis indicated that Spiolto Respimat reduces the frequency of night-time rescue medication use, as measured by puffs needed per night and these reductions were sustained for up to 52 weeks. In a third analysis the improvement of dyspnoea (or shortness of breath), as measured by the Transition Dyspnoea Index (TDI), was shown in COPD patients, compared to tiotropium, olodaterol and placebo. The most common adverse events in the TONADO 1&2 and OTEMTO 1&2 studies were nasopharyngitis (common cold), cough and back pain. Data were presented at the American College of CHEST Physicians Annual Meeting in Montreal.